Selecting an agent for prophylaxis of venous thromboembolism

Abstract

The Management Consultation column gives readers an opportunity to obtain advice on common management problems from pharmacists practicing in health systems.AJHP readers are invited to submit questions for this column. Selected questions will be forwarded to one or two experts in the field, who will prepare brief responses for publication. Questions should be narrow in scope, such that they can be answered in approximately 500 words. Responses will be sent to the inquirer before publication. Readers are also invited to comment on the answers of consultants; such comments will be considered for the Letters column.Suggestions for topics should be submitted to AJHP,

An Overview of Pulmonary Embolism

“…Several of these agents are currently approved for use in the United States: enoxaparin, dalteparin, and ardeparin. 14,15 While these medications are used to treat PE, these are also used as prophylaxis.…”